The company stated that the acquisition was intended to actively implement the country's call for children's health management and promote long-term balanced population development. At the same time, it would utilize the company's business advantages in in vitro diagnostics and Zhongshan Haiji's business advantages in growth hormone to promote the company's comprehensive strategic layout of "integrated diagnosis and treatment" and enhance the company's profitability.
However, competition in the growth hormone market is becoming increasingly fierce. Some institutions predict that the global market size will be approximately US3.4 billion in 2022, with a compound annual growth cyprus telegram data rate of approximately 8.1%, and is expected to reach a market size of US7.3 billion by 2032. The Chinese market is also showing a rapid growth trend. In 2021, the scale of China's growth hormone market exceeded 10 billion yuan, and exceeded 12 billion yuan in 2022.
As parents pay more attention to their children's dwarfism and medical technology continues to advance, it is expected that the penetration rate of growth hormone will increase to about 10% in the next 5-10 years, which will bring huge market growth space for the growth hormone industry.
This time, Shengxiang Bio has set its sights directly on the field of biologics in the pharmaceutical field.
According to the announcement, Shengxiang Bio plans to acquire 100% of the equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. for RMB 807.5 million in cash.